Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
TRENDS
Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
By Reiji Anasako Astellas Pharma sold 16 long-listed products (LLPs) to LTL Pharma, marking the first case in Japan where such older products are transferred to a company set up by an investment fund, and not to a pharmaceutical company.…
To read the full story
Related Article
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
- Astellas Unloading 16 Off-Patent Brands to LTL Pharma
March 29, 2017
TRENDS
- Top 10 PHARMA JAPAN Articles of 2025
December 23, 2025
- Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…